BioHorizons Adds Prolifica Allogeneic Growth Factor to Biomaterials Portfolio
New option uses biphasic protein release to support bone healing and tissue regeneration.
-
By
-
News Staff
-
August 26, 2026
Clinical Scorecard: BioHorizons Adds Prolifica Allogeneic Growth Factor to Biomaterials Portfolio
At a Glance
| Category | Detail |
|---|
| Condition | Bone healing and tissue regeneration |
| Key Mechanisms | Naturally occurring blend of allogeneic growth factors with biphasic release of proteins. |
| Target Population | Patients undergoing bone grafting procedures, particularly in the aging population. |
| Care Setting | Dental and surgical settings for hard tissue regenerative procedures. |
Key Highlights
- Prolifica contains a minimum of 16 proteins associated with cell growth and bone healing.
- Supports both standalone and combined bone grafting procedures.
- Designed to provide an initial and prolonged release of growth factors.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
Risks
Patient & Prescribing Data
Patients requiring advanced allograft solutions for complex hard tissue procedures.
Prolifica offers a high concentration of growth factors to enhance healing outcomes.
Clinical Best Practices
- Utilize Prolifica in conjunction with autologous bone or other allografts as needed.
- Consider the aging population's increased need for regenerative procedures.
Related Resources & Content
